Aetna Transplant and immunosuppressant appeal

Why Aetna (CVS Health) denies transplant and immunosuppressant

Aetna, owned by CVS Health since 2018, runs commercial group plans, Medicare Advantage, and a large pharmacy benefit footprint via Caremark. GLP-1, specialty drug, and behavioral health denials are the highest-volume categories.

For transplant and immunosuppressant specifically: Solid-organ transplant patients depend on continuous immunosuppressive therapy to prevent rejection. UNOS/OPTN guidelines establish that immunosuppressant regimens generally cannot be switched without significant clinical risk. Denials of transplant evaluation, listing, surgery, or maintenance immunosuppression are among the most clinically urgent appeals.

The law that controls this appeal

UNOS/OPTN clinical guidelines govern eligibility and continuity of care; Medicare Part B covers post-transplant immunosuppressants by statute.

What Aetna (CVS Health) denies for transplant and immunosuppressant

The transplant and immunosuppressant services most often denied:

Transplant evaluation and waitlisting
Transplant surgery (kidney, liver, heart, lung)
Specific brand of immunosuppressant (tacrolimus, mycophenolate, sirolimus)
Generic-to-brand switches denied
Anti-rejection biologic therapy
Out-of-network transplant centers

Why transplant and immunosuppressant claims get denied

A typical Aetna (CVS Health) transplant and immunosuppressant denial almost always cites one of these reasons. Each one maps to a specific rebuttal in the appeal:

Plan claims patient not medically eligible for transplant
Step therapy on immunosuppressants
Plan formulary forces switch from brand to generic
Out-of-network transplant facility
Post-transplant complications denied as unrelated

The Aetna (CVS Health) appeal process

Appeal levels: Internal level 1 (30 days standard / 72h urgent), then external IRO review (45 days standard).

Carrier timing: 180 days from denial for internal appeal; 60 days from final internal denial for external review.

Transplant timing: Urgent appeals: 72 hours. Standard: 30 days for prior auth, 60-180 days filing window. Transplant cases routinely qualify for expedited urgent review.

What we know about Aetna (CVS Health): Aetna's internal appeals respond well to peer-to-peer review requests filed alongside the written appeal.

Common Aetna (CVS Health) denial patterns for transplant and immunosuppressant

GLP-1 / Wegovy denials citing BMI. Aetna denies most weight-loss GLP-1 prescriptions citing BMI thresholds or 'lifestyle modification first' criteria. Switching the prescription path to a T2D-approved molecule (Ozempic, Mounjaro) when comorbidities exist often produces a same-week reversal.
Caremark formulary denials. Aetna's pharmacy benefit (Caremark) issues formulary denials separate from medical benefit denials. Each requires its own appeal track, confusing the two costs weeks.
Internal appeal then external review. Aetna's first appeal is internal and must be filed within 180 days. After internal denial, an external review by an Independent Review Organization (IRO) is available within 60 days, a separately strong reversal lane.

How to win your Aetna (CVS Health) transplant and immunosuppressant appeal

Strategy for transplant and immunosuppressant: Cite UNOS/OPTN clinical guidelines for transplant eligibility and continuity of care. For immunosuppressant switch denials, attach the treating transplant team's letter documenting the rejection risk from any regimen change. Many plans have specific transplant carve-out networks (Centers of Excellence), confirm in-network status of the specific center before assuming OON. Medicare Part B covers immunosuppressants post-transplant under federal law.

Filed against Aetna (CVS Health), that strategy rides on this procedural spine:

Procedural-rights anchor. Every Aetna (CVS Health) denial triggers ERISA § 503 or 45 C.F.R. § 147.136 procedural rights. The cover letter invokes these in the opening paragraph to lock the timeline and force criteria disclosure.
Criteria-disclosure demand. Aetna (CVS Health) frequently denies on "not medically necessary" without disclosing the clinical criteria applied. Once disclosed, those criteria become the rebuttal map.
Controlling-standard citation. UNOS/OPTN clinical guidelines govern eligibility and continuity of care; Medicare Part B covers post-transplant immunosuppressants by statute.
Treating-provider attestation. A letter from the treating physician addressing each criterion in Aetna (CVS Health)'s own policy language. This is the single strongest evidentiary element.
Requested action. A specific demand to reverse the transplant and immunosuppressant denial and approve the service, not a general "please reconsider."

Documents you'll need for your Aetna (CVS Health) transplant and immunosuppressant appeal

Denial letter
Transplant team's letter and treatment plan
UNOS / center listing documentation
Lab values supporting transplant indication
Prior immunosuppressant trial history (if relevant)

What a transplant and immunosuppressant appeal can recover

Typical recovery for transplant and immunosuppressant cases runs $10,000 - $1,000,000+. The exact figure depends on the specific service and your plan's contracted rates.

Aetna (CVS Health) transplant and immunosuppressant appeals: frequently asked questions

Can I appeal your Aetna (CVS Health) transplant or immunosuppressant denial?

Yes, and these are among the most clinically urgent appeals. Cite UNOS/OPTN clinical guidelines for eligibility and continuity of care, and request expedited 72-hour review where rejection risk is in play.

Can Aetna (CVS Health) force me to switch immunosuppressants?

You can contest it. UNOS/OPTN guidance is that immunosuppressant regimens generally cannot be switched without significant rejection risk; attach your transplant team's letter documenting that risk for any forced brand-to-generic or formulary switch.

Is my transplant center in network?

Many plans use specific transplant Centers of Excellence networks. Confirm the center's status before assuming it is out of network, because a carve-out network often covers a center that the general directory does not list.

Are post-transplant drugs covered by Medicare?

Yes. Medicare Part B covers immunosuppressive drugs following a covered transplant by federal law, which is a direct counter to a maintenance-immunosuppression denial.

What Apellica does for Aetna (CVS Health) transplant and immunosuppressant appeals

We file appeals against Aetna (CVS Health) specifically configured to its internal review process. Every transplant and immunosuppressant appeal embeds the criteria-disclosure demand, the procedural-rights anchor, the controlling-standard citation above, treating-provider attestation language, and the peer-reviewed evidence relevant to the denied service.

Cost: $0 upfront. We work on contingency for Aetna (CVS Health) appeals, if the appeal succeeds, we collect a percentage of the recovered claim value. If it fails, you owe nothing.

Start your Aetna (CVS Health) transplant and immunosuppressant appeal

Submit a 2-minute intake. A senior reviewer responds within one business day with the specific appeal strategy for your case.

Start free appeal review →

How to appeal your Aetna (CVS Health) transplant and immunosuppressant denial